Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 9th Annual Meeting on Arrhythmia and Cardiac Surgery Brisbane, Australia.

Day 1 :

Keynote Forum

Guy Salama

University of Pittsburgh School of Medicine,USA

Keynote: Molecular basis of sex-differences in arrhythmia risk or how can Ca2+-overload generate Torsade de Pointes

Time : 10:15-10:55

OMICS International Arrhythmia 2016 International Conference Keynote Speaker Guy Salama photo

Guy Salama completed his PhD in Biophysics and Biochemistry and a Post-doctroal fellowship at the University of Pennsylvania. He is a pioneer in the development of optical probes of membrane potential, high spatial and temporal-resolution imaging of electrical activity and Ca2+ transients and the elucidation of arrhyhtmia mechanisms. He has made significant contributions to elucidate the mechanisms underlying sex differences in long QT-related arrhyhtmias and demonstrated the genomic modulation of cardiac ion channels by estrogen. He has published more than 125 papers in top-tiered journals and has served on numerous study sections for the NIH and the AHA. rnrn


Drug-induced Long QT type 2 (LQT2) is a serious public health problem in terms of safety pharmacology, because many cardiac and non-cardiac drugs inhibit the rapid component of the delayed rectifying K+ current, IKr resulting in action potential duration (APD) and QT prolongation resulting in lethal polymorphic ventricular arrhythmias called Torsade de Pointes (TdP). Despite decades of research, the mechanisms of LQT2-related TdP in man, and why women are at a greater risk of TdP, remain controversial. In clinical and rabbit models, female sex confers a considerably greater risk to TdP which has been attributed sex-differences in ‘repolarization reserve’. This theory posits that female hearts have reduced IKr compared to males due to IKr inhibition and stimulation, respectively by estrogen (17β-estradiol, E2) and dihydrotestosterone (DHT). Our group has challenged this theory and shown that Ca2+-overload at the base of female rabbit hearts initiate TdP in drug-induced LQT2. TdP is initiated by early afterdepolarizations (EADs) which appear first at the base of the heart and are preceded by intracellular Ca2+ (Cai) oscillations during prolonged APDs. Adult females have higher L-type Ca2+ current, ICa,L and Na-Ca exchange current, INCX in myocytes from the base of the epicardium (where EADs are initiated) compared to myocytes from the apex, or from the endocardium. The up-regulation of these currents occurs via genomic upregulations (↑Cav1.2α, β2 subunits, and ↑NCX1 and their mRNA) by E2 (0.3-1 nM). Genomic regulation of Cav1.2α, β2 subunits was mediated by estrogen receptor α, ERα but not the β subtype, ERβ. Dual optical mapping of APs and Ca2+ transients (at subcellular spatial resolution (1.5x1.5 µm2)) shows that repolarization delay (bradycardia or LQT2) in female hearts causes Ca2+ overload and synchronous spontaneous sarcoplasmic reticulum (SR) Ca2+ release during systole, initiating EADs at the base of the ventricles. Synchronous systolic Ca2+ elevation from islands of epicardium as small as ~0.5 mm dia. can elicit EADs and TdP. Findings in rabbit hearts are shown for the first time to apply to human sex differences by testing the effects of estrogen in male and female human iPS-CMs and by Western blot analysis of regional heterogeneities of ion channel expression in the heart of adult men, women and post-menopausal women.

Break: Networking & Refreshment Break 10:55-11:10 @ Quay Restaurant

Keynote Forum

Darren Walters

Prince Charles Hospital, Australia

Keynote: Pacemaker rates in TAVI and influence of device design

Time : 14:10-14:50

OMICS International Arrhythmia 2016 International Conference Keynote Speaker Darren Walters photo

Darren Walters has been the Director of Cardiology at The Prince Charles Hospital from 2005, an Interventional Cardiologist from 2001, and Executive Chair of the Prince Charles Hospital Heart and Lung Institute. He also was the Executive Director of the Prince Charles Hospital for 18 months from February 2013 and acted as Executive Director of the RBWH for a period during a time of change and stabilisation. He was trained at The Prince Charles Hospital and then as a Clinical and Research Fellow in Interventional Cardiology at Massachusetts General Hospital, Harvard Medical School, Boston 2000-2001. He is a Professor of Medicine University of Queensland, and a graduate of the UQ Medical School. He has held roles as Chair of the Prince Charles Hospital Medical Advisory Council, Member of the Prince Charles Hospital Executive Council and Chair of the Central Area Cardiac Network. He is past Chair of the Interventional Working Group of the Cardiac Society of Australia and New Zealand and the Cardiac Society representative Chair of the ACS subcommittee of the Australian Resuscitation Council. He is a member of the ILCOR task force on ACS-myocardial infarction. He is involved in International prospective randomised trials and investigator driven translational research in interventional cardiology and is the author of more than 150 peer reviewed papers, abstracts and book chapters. He has been an invited expert in more than half a dozen countries overseas including the USA, Europe, Japan, Hong Kong, Malaysia, Thailand, Singapore and China. He is one of Australia’s leading interventional cardiologist in the field of structural heart disease


Not to be published